Markus Hinder

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
New drugs serving unmet medical needs are one of the key value drivers of research-based pharmaceutical companies. The efficiency of research and development (R&D), defined as the successful approval and launch of new medicines (output) in the rate of the monetary investments required for R&D (input), has declined since decades. We aimed to identify,(More)
  • 1